LumiraDx to Go Public on Nasdaq Through SPAC

Apr 07, 2021

|

NEW YORK – Special purpose acquisition company (SPAC) CA Healthcare Acquisition on Wednesday announced a merger agreement with point-of-care diagnostic testing firm LumiraDx.

The merger with CA Healthcare Acquisition would facilitate the listing of London-based LumiraDx on the Nasdaq under the ticker symbol LMDX.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Performance of SARS-CoV-2 Assay in Extraction-free Method Compared to that of Conventional RNA Extraction using Automated Instrument

The Importance of Sample Pooling in COVID-19 Testing

The Importance of Limit of Detection in COVID-19 Tests

How To Start COVID-19 Testing In Your Lab

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

May

10

Featured Webinar

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May

18

Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.

Menu

LumiraDx to Go Public on Nasdaq Through SPAC

To read the full story....

Breaking News

FDA Grants First ASCA Accreditations to Labs to Perform Premarket Testing

Top Five Articles on 360Dx Last Week: NIH RADx, LumiraDx, Abbott, And More

Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

DiaSorin to Acquire Luminex for $1.8B

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Featured White Papers

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

DiaSorin to Acquire Luminex for $1.8B

CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

FDA Issues First EUA for COVID-19 Antibody Test Using Self-Collected Blood Samples

Sponsorships